Brokerages expect Recro Pharma Inc (NASDAQ:REPH) to announce ($0.75) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Recro Pharma’s earnings, with estimates ranging from ($1.00) to ($0.59). Recro Pharma reported earnings of ($0.63) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 19%. The business is expected to report its next earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that Recro Pharma will report full-year earnings of ($2.66) per share for the current financial year, with EPS estimates ranging from ($2.92) to ($2.50). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.75) per share, with EPS estimates ranging from ($3.71) to ($2.05). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Recro Pharma.
Recro Pharma (NASDAQ:REPH) last issued its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.03. The firm had revenue of $18.28 million during the quarter, compared to analyst estimates of $16.77 million. Recro Pharma had a negative net margin of 79.42% and a negative return on equity of 220.42%.
A number of equities analysts have weighed in on the stock. Oppenheimer set a $18.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a research report on Wednesday, September 5th. ValuEngine upgraded shares of Recro Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, September 4th. Zacks Investment Research lowered shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Saturday, November 10th. Piper Jaffray Companies set a $10.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a research report on Thursday, November 8th. Finally, Janney Montgomery Scott set a $13.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a research report on Monday, October 1st. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Recro Pharma presently has an average rating of “Buy” and a consensus price target of $12.88.
Hedge funds have recently added to or reduced their stakes in the company. Engine Capital Management LP raised its holdings in Recro Pharma by 21.0% during the 3rd quarter. Engine Capital Management LP now owns 473,484 shares of the specialty pharmaceutical company’s stock valued at $3,366,000 after buying an additional 82,177 shares during the period. Renaissance Technologies LLC increased its stake in Recro Pharma by 26.0% in the third quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock worth $3,416,000 after purchasing an additional 99,200 shares during the period. Virtu Financial LLC purchased a new stake in Recro Pharma in the third quarter worth $156,000. Panagora Asset Management Inc. increased its stake in Recro Pharma by 1,361.1% in the third quarter. Panagora Asset Management Inc. now owns 189,128 shares of the specialty pharmaceutical company’s stock worth $1,345,000 after purchasing an additional 176,184 shares during the period. Finally, Acadian Asset Management LLC increased its stake in Recro Pharma by 29.5% in the third quarter. Acadian Asset Management LLC now owns 290,124 shares of the specialty pharmaceutical company’s stock worth $2,063,000 after purchasing an additional 66,062 shares during the period. Institutional investors own 52.20% of the company’s stock.
Shares of NASDAQ:REPH opened at $7.54 on Tuesday. The company has a debt-to-equity ratio of 4.04, a current ratio of 1.36 and a quick ratio of 1.16. The stock has a market cap of $151.85 million, a price-to-earnings ratio of -3.79 and a beta of -0.51. Recro Pharma has a twelve month low of $4.78 and a twelve month high of $13.05.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Recommended Story: Understanding Analyst Ratings
Get a free copy of the Zacks research report on Recro Pharma (REPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.